Additionally, two-thirds of all SCLC patients are diagnosed at extensive stage3. DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated with poor ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody ... ZL-1310 targets DDL3, an antigen overexpressed in ...

DLL3 is an antigen with low expression in normal tissues, but is significantly overexpressed in certain solid tumours, making it an attractive drug target. Early drug development attempts ran into ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin ... CD3/T-cells only when binding to tumor-associated antigens, while remaining inactive in circulation.

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

Our first Radio-DARPin program, MP0712, targeting DLL3, is well advanced and on track ... CD3/T-cells only when binding to tumor-associated antigens, while remaining inactive in circulation.

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...